November 2022 in “The Caucasus” The document's conclusion cannot be provided because the content is not in a readable format.
21 citations
,
January 2021 in “Frontiers in Pharmacology” Thiopurines help treat IBD but require genetic testing to avoid side effects.
November 2016 in “Hair transplant forum international” Hair transplant surgery should only be done by licensed professionals, as many states don't allow unlicensed personnel to perform it.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
2 citations
,
October 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” AIRE deficiency causes hair loss similar to alopecia areata in mice.
3 citations
,
August 2013 in “Maǧallaẗ ǧāmiʻaẗ al-anbār li-l-ʻulūm al-ṣirfaẗ” Thyroid and reproductive hormones, BMI, and excess hair are linked in Iraqi women with PCOS.
36 citations
,
January 2010 in “International Journal of Trichology” Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
May 2023 in “Journal of Cosmetic Dermatology” Androgenetic alopecia is linked to higher cardiovascular and metabolic risks, possibly due to irisin resistance.
24 citations
,
July 1994 in “Journal of Investigative Dermatology” September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
March 2005 in “Hair transplant forum international”
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
September 2021 in “Revista Interdisciplinar em Saúde” Oral isotretinoína effectively stabilizes frontal fibrosing alopecia.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
19 citations
,
May 2022 in “International journal of molecular sciences” PRX01, PRX44, and PRX73 are essential for root hair growth in Arabidopsis thaliana.
6 citations
,
July 2024 in “Heliyon” Steroid 5α-reductase evolved from protists and diversified in eukaryotes, with specific roles in mammals and plants.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
15 citations
,
October 1996 in “Archives of Dermatology” Researchers identified a new hair loss pattern called "sisaipho type," where hair is lost across the scalp except around the edges.
174 citations
,
July 2003 in “The Journal of Clinical Endocrinology & Metabolism” Five new mutations in the androgen receptor gene were found, helping to understand androgen insensitivity syndrome better.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
January 2020 in “The Journal of Sexual Medicine” Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.
6 citations
,
August 2021 in “Clinical Epidemiology” Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
February 2025 in “Iranian journal of pharmaceutical research” 3 citations
,
July 2022 in “Brain and Behavior” The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.